Navigation Links
Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Mar 19, 2007 - Acorda Therapeutics (Nasdaq: ACOR) today announced that Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at the University of Rochester, will present data from Acorda's MS-F203 Phase 3 clinical trial of Fampridine-SR in multiple sclerosis at the upcoming American Academy of Neurology (AAN) meeting. The platform presentation will take place on Wednesday May 2, 2007 at 4:15 pm Eastern Time (ET). This abstract was also selected to be part of the Scientific Highlights program, which spotlights the top five percent of the more than 1600 abstracts accepted for presentation at this meeting. The AAN meeting will take place at the Hynes Convention Center in Boston, MA.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeut ics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Contact

Acorda Therapeutics
Erica Wishner, 914-347-4300 ext. 162
ewishner@acorda.com


'"/>




Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
3. Acorda Therapeutics to Host Analyst and Investor Reception
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 22, 2017 Orthopedic and cardiac devices ... aging demographic patterns lead to an increasing prevalence ... and exercise-related injuries, chronic back problems, heart valve ... gains. The future of medical implants faces many ... questions and more: - What types of ...
(Date:2/23/2017)... 23, 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... report its fourth quarter and full year 2016 financial ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... event can be obtained as follows: Thursday, ...
(Date:2/22/2017)... Calif. , Feb. 22, 2017 IRIDEX ... it will release financial results for the fourth quarter ... March 8, 2017.  The Company,s management team will host ... / 5:00 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified ... from the mouth into the bloodstream. Far outpacing the absorption speed ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ANGLESTRONG ... Kurt Angle, is now available on the App Store and Google ... mobile apps for the addiction and recovery industry, partnered with Angle to build ANGLESTRONG. ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... launch of ProGen™ PRP, the latest innovation in the delivery of Platelet Rich ... care, aesthetics, cardiovascular and pain management, to accelerate tissue synthesis and provide a ...
(Date:2/22/2017)... Switzerland (PRWEB) , ... February 22, 2017 , ... ... difficulty hearing and 72 percent of those report that family members or friends ... who think they suffer from hearing loss wear hearing aids. One reason, suggested ...
(Date:2/22/2017)... Carolina (PRWEB) , ... February 22, 2017 , ... Pet ... cats and 54% of dogs, according to the Association for Pet Obesity Prevention (APOP). ... on key pet food issues such as the benefits of corn and grains, value ...
Breaking Medicine News(10 mins):